Caas Capital Management LP Candel Therapeutics, Inc. Transaction History
Caas Capital Management LP
- $1.31 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding CADL
# of Institutions
22Shares Held
3.86MCall Options Held
0Put Options Held
0-
Northpond Ventures, LLC1.94MShares$12.1 Million8.58% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA812KShares$5.07 Million0.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA541KShares$3.38 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$910,6620.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX82.6KShares$516,2180.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $181M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...